Article

Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development – Commonalities and differences in portfolio management practice

Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

The concept of portfolio management has been widely used in the pharmaceutical industry. It is used to evaluate the commercial value and the risk structure of development projects. The final goal is to select a portfolio of projects that addresses the strategic objectives of the organisation optimally and that leads to the highest overall portfolio value. Companies now start to apply the portfolio management concept on their research portfolios. Although the basic principle remains the same, the methodology applied has to be adapted to the greater uncertainty that early research projects carry. Commonalities and differences of the portfolio management process in research and development are described and recommendations are given how to harmonise the two different approaches.

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the authors.

ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
This paper explains a comprehensive and systematic approach to evaluate drug development projects and technology platforms, using an augmented version of net present value (NPV). The benefits of financial models for value-driven project and portfolio management, licensing negotiations and investors' decisions are discussed.Journal of Commercial Biotechnology (2005) 11, 155-170; doi:10.1057/palgrave.jcb.3040113
Article
Full-text available
An empirical analysis indicates that the order of entry of a brand into a consumer product category is inversely related to its market share. Market share is modeled as a log linear function of order of entry, time between entries, advertising, and positioning effectiveness. The coefficients of the entry, advertising, and positioning variables are significant in a regression analysis on an initial sample of 82 brands across 24 categories. These findings are confirmed by predictions on 47 not previously analyzed brands in 12 categories. Managerial implications for pioneers and later entrants are identified.
Article
Full-text available
Three established and four emerging empirical generalizations are identified below. The first established generalization is that there is a negative relationship between order of market entry and market share. Second, for consumer packaged goods and prescription anti-ulcer drugs, the entrant's market share divided by the first entrant's share roughly equals one divided by the square root of order of market entry. Third, in mature markets, market pioneer share advantages slowly decline over time. While the emerging generalizations require additional research support, the initial findings suggest: (1) for consumer packaged goods, order of market entry has a stronger negative relationship with trial penetration than with repeat purchase; (2) market pioneers have broader product lines than late entrants; (3) skill and resource profiles differ across market pioneers, early followers, and late entrants; and (4) order of market entry is not related to long-term survival rates. Future research topics are also discussed.
Article
Full-text available
Legislation to create a regulatory pathway for follow-on biologics is currently being considered by the United States Congress. A critical issue in this respect is the period of data exclusivity for innovator companies before a follow-on competitor can rely in part on data obtained for an original biologic for an abbreviated approval. Given the nature of patents on biologics, the period of data exclusivity is anticipated to have a key role in determining how quickly follow-on competitors emerge, and consequently also on the time available for originator companies to recoup their investment. With this issue in mind, this article discusses factors influencing return on investment on biologic research and development. A break-even analysis for a representative portfolio of biologics provides support for a substantial data exclusivity period.
Article
This paper explains a comprehensive and systematic approach to evaluate drug development projects and technology platforms, using an augmented version of net present value (NPV). The benefits of financial models for value-driven project and portfolio management, licensing negotiations and investors' decisions are discussed.
Article
OVER THE PAST DECADES, THERE HAVE BEEN MANY BREAKthroughs in the discovery and development of new medications to treat diseases. Yet a number of devastating human ailments still cannot be treated effectively with drugs. Cancer, autoimmune diseases, circulatory conditions, neurodegeneration, and other ills continue to resist medicinal intervention to one degree or another. Researchers in academia, government, and the pharmaceutical industry wage battle against these diseases and win many victories. But questions have been raised about whether their efforts are as effective as they could be. Has the efficiency of drug discovery and development slipped? If so, how can the process be improved? Many people are endeavoring to answer these questions. Data indicate that the productivity of the pharmaceutical industry has slipped in recent years. A study last year ( J. Am. Med. Assoc. 2005 , 294 , 1333) showed that U.S. biomedical research funding (adjusted for inflation) rose from $48 billion to ...
Article
Portfolio planning has been the subject of much debate, but little testing in strategic management. Building on the assumptions that relative ROA and sales growth are valid indicators of competitive position and industry attractiveness, this study examines whether an investment strategy that is consistent with prescriptions from the general portfolio model is associated with excess returns to shareholders. Evidence reported in this study indicates that this strategy is actually associated with subpar returns to shareholders. The implications of this finding for scholars and managers are discussed.
Article
Investment in the development of biogenerics is frequently seen as a means to escape the intense price competition that characterises the generics market. As the costs of goods sold are much higher for biopharmaceuticals than for synthetic, small molecule drugs, however, and successful market penetration may be more difficult to achieve, economic profitability is not guaranteed. One way to avoid unpleasant surprises is to invest early in the development of economic models that allow decision makers to understand the risks, rewards and sensitivities of the biogenerics business before significant investments are committed. As pricing will be decisive for commercial success or failure, careful pricing studies, such as conjoint analyses, are suggested.
Article
Many companies in the biotechnology industry have significant valuations despite having no product revenue because their products are in early stages of development. In the past 10-15 years, investors have bid up the stock prices of companies showing promise of developing a blockbuster drug. We explain the decision-tree method and binomial-lattice method (which adds a growth option) and use them to value a biotechnology company, Agouron Pharmaceuticals, as the sum of the values of its drug-development projects. The growth option was added because the development of an initial new molecular entity (NME) is similar to purchasing a call option on the value of a subsequent NME. We compare our computed values of Agouron with actual market values at selected points in time during the development of Agouron's Viracept, a drug used to treat HIV-positive patients.
Article
Biotechnology investors are increasingly concerned about taking the risk of investing in the development of innovative drugs, and pharmaceutical companies are worried about maintaining their high profitability in the future. The question is how to build a portfolio of research and development (R&D) projects that fulfils the financial expectations of investors and shareholders. State-of-the-art net present value algorithms are applied to different types of projects at entry into development in order to evaluate their financial attractiveness and their ability to generate adequate returns. Based on the currently applied cost of capital for pharmaceutical and biotechnology companies the attractiveness of the so-called blockbuster model is clearly supported. The increasingly favoured specialty model, however, will only provide sufficient returns to biotechnology investors if significant sales volumes are reached. Complementing a company's development portfolio with risk-reduced projects could be an attractive way to ensure sustained growth for both biotechnology and pharmaceutical companies.
Article
We provide a Poisson real option model of a gene-to-drug venture. First we describe a general new drug discovery programme as well as a specific secretory protein research programme. Then we model both the candidate secretory gene and the ‘hot’ gene discoveries as Poisson processes. Gene deal value sizes are modeled as lognormal distributions. Then we calculate the expected R&D value (EV) of the Poisson discoveries times the value distributions, for both stages. Finally, for generic collaborating-funding arrangements, we show the Merton (1976) standard mixed diffusion-jump option value, compared to a risk neutral ‘intrinsic’ value. Under simple assumptions, the real option value is substantial, even if there is no intrinsic value.
Article
The transformation of drug discovery in the past decade will result in an expanding array of novel development candidates that will outstrip the development resources of even the largest pharmaceutical companies. A critical success factor for drug companies will be their ability to maximize the value of their development portfolios by focusing finite resources on projects with real potential. Successful management of the research-to-development interface will require better quality decision making in the selection of entrants to development and in portfolio management. Clarity in defining the product opportunity in the challenging new pharmaceutical marketplace will be crucial to such decision making.
Article
Major resource-allocation decisions are never easy. For a pharmaceuticals company like SmithKline Beecham, the problem is this: How do you make good decisions in a high-risk, technically complex business when the information you need to make those decisions comes largely from the project champions who are competing against one another for resources? In 1993, the company experimented with ways of depoliticizing the process and improving the quality of decision making. In most resource-allocation processes, project advocates develop a single plan of action and present it as the only viable approach. In SB's new process, the company found an effective way to get around the all-or-nothing thinking that only reinforces the project-champion culture. Project teams were required--and helped--to create meaningful alternatives to current development plans. What would they do with more money? With less? With none at all? In another important departure from common practice, SB separated the discussion of project alternatives from their financial evaluations. In doing so, SB was able to avoid the premature evaluations that kill both creativity and the opportunity to improve decision making. The new process at SB has allowed the organization to spend less time arguing about how to value its R&D projects and more time figuring out how to make them more valuable. In the end, the company learned that by tackling the soft issues around resource allocation--such as information quality, credibility, and trust--it had also addressed the hard ones: how much to invest and where to invest it.
Article
The pharmaceutical industry faces considerable challenges, both politically and fiscally. Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny. In the United States, drug costs are also the subject of intense political discourse. This article deals with the fiscal pressures that face the industry from the perspective of R&D. What impinges on productivity? How can we improve current reduced R&D productivity?
Article
Innovative drug developers are facing an unprecedented number of challenges in maintaining revenue growth. Fewer novel drugs are being approved, a large number of blockbusters are facing patent expiry, and public and private payers across the major drug markets are implementing cost-containment policies in response to sky-rocketing healthcare costs, which is affecting drug margins.
Article
During the 1980s the share of prescriptions sold by retail pharmacies that was accounted for by generic products roughly doubled. The price response to generic entry of brand-name products has been a source of controversy. In this paper we estimate models of price responses to generic entry in the market for brand-name and generic drugs. We study a sample of 32 drugs that lost patent protection during the early to mid-1980s. Our results provide evidence that brand-name prices increase after generic entry and are accompanied by large decreases in the price of generic drugs. Copyright (c) 1997 Massachusetts Institute of Technology.
  • M Cervantes
Cervantes, M. (2004) www.AutomotiveForums.com, 12 August.
Establishing portfolio value metrics , in , 7th Annual Rx and Biotech Portfolio Management Conference
  • D Townson
Townson, D. ( 2006 ). Establishing portfolio value metrics, in, 7th Annual Rx and Biotech Portfolio Management Conference, January 2006, Philadelphia. 10. www.fda.gov/cder/meeting/riskmanagement.htm.
Pharmaceutical project and portfolio management -Effective organization and decision making
  • S Seget
Seget, S. ( 2005 ). Pharmaceutical project and portfolio management -Effective organization and decision making. Business Insights, Business Insights Ltd.
Effective portfolio, project management, and resource allocation for enhanced competitiveness , presented at Drivers, Roles And Challenges of Portfolio and Project Management in Pharmaceutical Industry Conference
  • N Ahmed
Ahmed, N. ( 2005 ). Effective portfolio, project management, and resource allocation for enhanced competitiveness, presented at Drivers, Roles And Challenges of Portfolio and Project Management in Pharmaceutical Industry Conference, May 2005, Brussels.
The management of risk in pharmaceutical R & D , in , The R & D Management Conference
  • K Bode-Greuel
Bode-Greuel, K. ( 2007 ). The management of risk in pharmaceutical R & D, in, The R & D Management Conference 2007, July 2007, Bremen. 12. www.fda.gov.
Pharmaceutical portfolio management -What's working, what's not?
  • R Heaslip
Heaslip, R. ( 2005 ). Pharmaceutical portfolio management -What's working, what's not? DIA Annual Meeting, June 2005.
  • Young Ernst
Ernst & Young, Global Report 2005
  • S D Roger
  • M D Frac
  • D Goldsmith
Roger SD, Frac MD and Goldsmith D (2008), Journal of Clinical Pharmacy and Therapeutics Vol. 33, 459-464
  • G Mijuk
Mijuk G, The Wall Street Journal, 31.1.2011
Valuation of biosimilar products and pipelines, DZ Bank
  • E Kraus
Kraus, E (2010), Valuation of biosimilar products and pipelines, DZ Bank, Germany, published in: Life Science in the Capital Market-Biosimilars.
  • M Cervantes
Cervantes, M. (2004) www.AutomotiveForums.com, 12 August.
Improving effi ciency
  • S Borman
Borman, S. ( 2006 ). Improving effi ciency. Chem. Eng. News 84 (25), 56 -78.
Managing the drug discovery/ development interface: can the pharmaceutical industry reduce attrition rates?
  • T Kennedy
Kennedy, T. ( 1997 ). Managing the drug discovery/ development interface: can the pharmaceutical industry reduce attrition rates? Drug Discov. Today 2 (10), 436 -444. management more effective. Research-Technol. Manage., March -April, pp. 18 -33.
Drug discovery at Merck Serono -striving for best pharma
  • B Kirschbaum
Kirschbaum, B. ( 2007 ). Drug discovery at Merck Serono -striving for best pharma, in, R & D Leaders ' Forum, October 2007, Munich.
presented at Portfolio Optimization for Pharmaceuticals Conference
  • P Nakagaki
Nakagaki, P. ( 2001 ). presented at Portfolio Optimization for Pharmaceuticals Conference, November 2001, London.
Risk assessment of drug discovery projects as an integral part of portfolio management , Thesis for the Master of Science in Pharmaceutical Medicine
  • M Zoche
Zoche, M. ( 2007 ). Risk assessment of drug discovery projects as an integral part of portfolio management, Thesis for the Master of Science in Pharmaceutical Medicine, University of Duisburg-Essen, April 2007.
Using decision analysis and portfolio management to enhance R & D performance , presented at Drivers, Roles and Challenges of Portfolio and Project Management in Pharmaceutical Industry Conference
  • A Artuso
Artuso, A. ( 2005 ). Using decision analysis and portfolio management to enhance R & D performance, presented at Drivers, Roles and Challenges of Portfolio and Project Management in Pharmaceutical Industry Conference, May 2005, Brussels.